<!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <title>骨肉瘤驅動基因分析報告</title>
    <style>
        body { font-family: "Microsoft JhengHei", sans-serif; margin: 20px; }
        h2 { color: #2c3e50; border-bottom: 2px solid #3498db; padding-bottom: 5px; }
        table { border-collapse: collapse; width: 100%; margin-bottom: 20px; }
        th { background-color: #3498db; color: white; text-align: left; }
        td, th { border: 1px solid #ddd; padding: 8px; }
        tr:nth-child(even) { background-color: #f2f2f2; }
        .high-risk { background-color: #ffebee !important; }
        .mod-risk { background-color: #fff8e1 !important; }
        .gene-impact { display: inline-block; width: 12px; height: 12px; border-radius: 50%; margin-right: 5px; }
        .high-impact { background-color: #e53935; }
        .medium-impact { background-color: #ffb300; }
        .low-impact { background-color: #43a047; }
    </style>
</head>
<body>
    <h2>骨肉瘤核心驅動基因分析</h2>
    <table>
        <thead>
            <tr>
                <th>基因</th>
                <th>突變類型</th>
                <th>致癌機制</th>
                <th>骨肉瘤關聯證據</th>
                <th>臨床意義</th>
                <th>功能影響</th>
            </tr>
        </thead>
        <tbody>
            <tr class="high-risk">
                <td>TP53</td>
                <td>R273C</td>
                <td>
                    <ul>
                        <li>DNA損傷修復失能</li>
                        <li>基因組不穩定性增加</li>
                        <li>細胞凋亡抑制</li>
                    </ul>
                </td>
                <td>
                    ★★★★★<br>
                    >90%骨肉瘤存在TP53突變<br>
                    TCGA肉瘤數據庫確認
                </td>
                <td>預後不良標誌物<br>化療抗性預測因子</td>
                <td><span class="gene-impact high-impact"></span>高</td>
            </tr>
            <tr class="high-risk">
                <td>CDKN2A</td>
                <td>D74N, A68V</td>
                <td>
                    <ul>
                        <li>p16<sup>INK4a</sup>蛋白功能喪失</li>
                        <li>Rb通路異常激活</li>
                        <li>細胞週期失控</li>
                    </ul>
                </td>
                <td>
                    ★★★★☆<br>
                    75%骨肉瘤存在CDKN2A缺失/突變<br>
                    Nature Genetics 2020確認
                </td>
                <td>腫瘤早期驅動事件<br>轉移風險增加</td>
                <td><span class="gene-impact high-impact"></span>高</td>
            </tr>
            <tr class="high-risk">
                <td>ATRX</td>
                <td>E1639*</td>
                <td>
                    <ul>
                        <li>染色質重塑功能障礙</li>
                        <li>端粒維持異常</li>
                        <li>表觀遺傳失調</li>
                    </ul>
                </td>
                <td>
                    ★★★★☆<br>
                    兒童骨肉瘤突變率15-20%<br>
                    Science 2019研究確認
                </td>
                <td>促進腫瘤異質性<br>放療敏感性降低</td>
                <td><span class="gene-impact high-impact"></span>高</td>
            </tr>
            <tr class="mod-risk">
                <td>STK11</td>
                <td>L282fs*3</td>
                <td>
                    <ul>
                        <li>AMPK/mTOR通路失調</li>
                        <li>細胞代謝紊亂</li>
                        <li>極性喪失</li>
                    </ul>
                </td>
                <td>
                    ★★★☆☆<br>
                    Peutz-Jeghers症候群關聯<br>
                    骨肉瘤風險增加50倍
                </td>
                <td>遺傳性骨肉瘤標誌<br>代謝重編程驅動</td>
                <td><span class="gene-impact medium-impact"></span>中</td>
            </tr>
        </tbody>
    </table>

    <h2>潛在相關基因驗證需求</h2>
    <table>
        <thead>
            <tr>
                <th>基因</th>
                <th>突變類型</th>
                <th>可能機制</th>
                <th>實驗驗證建議</th>
                <th>現有證據等級</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>B2M</td>
                <td>S16fs, L15fs</td>
                <td>MHC-I複合物缺失導致的免疫逃逸</td>
                <td>免疫組化驗證HLA表達<br>PD-1抑制劑敏感性測試</td>
                <td>★★☆☆☆ (小鼠模型顯示關聯)</td>
            </tr>
            <tr>
                <td>BCOR</td>
                <td>G400fs*42</td>
                <td>表觀遺傳調控異常<br>(PRC1.1複合物失能)</td>
                <td>ChIP-seq分析H2A泛素化<br>成骨細胞分化實驗</td>
                <td>★★☆☆☆ (肉瘤亞型報告)</td>
            </tr>
            <tr>
                <td>MAP2K1</td>
                <td>K57T</td>
                <td>MAPK信號通路持續激活</td>
                <td>ERK磷酸化檢測<br>MEK抑制劑體外敏感性</td>
                <td>★★★☆☆ (骨肉瘤細胞系證據)</td>
            </tr>
        </tbody>
    </table>

    <h2>排除基因清單及科學依據</h2>
    <table>
        <thead>
            <tr>
                <th>基因</th>
                <th>排除原因</th>
                <th>主要相關疾病</th>
                <th>參考文獻</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>UGT1A1</td>
                <td>膽紅素代謝基因，與致癌過程無直接關聯</td>
                <td>吉伯特氏症候群</td>
                <td>Pharmacogenomics J. 2014</td>
            </tr>
            <tr>
                <td>FH</td>
                <td>三羧酸循環酶基因，缺乏骨肉瘤關聯證據</td>
                <td>遺傳性平滑肌瘤病</td>
                <td>Nat Rev Cancer. 2021</td>
            </tr>
            <tr>
                <td>GNAS</td>
                <td>G蛋白偶聯受體信號，影響內分泌腫瘤</td>
                <td>McCune-Albright症候群</td>
                <td>Endocr Rev. 2018</td>
            </tr>
            <tr>
                <td>APC</td>
                <td>WNT通路調控，典型結直腸癌基因</td>
                <td>家族性腺瘤性息肉病</td>
                <td>Cell. 2020</td>
            </tr>
            <tr>
                <td>MLH1</td>
                <td>錯配修復基因，微衛星不穩定表型</td>
                <td>林奇症候群</td>
                <td>J Clin Oncol. 2019</td>
            </tr>
        </tbody>
    </table>

    <h2>關鍵結論與建議</h2>
    <h3>致癌機制分析</h3>
    <ul>
        <li><strong>核心通路破壞：</strong> TP53-CDKN2A軸突變導致基因組不穩定性+細胞週期失控</li>
        <li><strong>表觀遺傳失調：</strong> ATRX/BCOR突變引發染色質結構異常</li>
        <li><strong>微環境交互：</strong> B2M缺失創造免疫豁免微環境</li>
    </ul>
    
    <h3>功能驗證優先級</h3>
    <ol>
        <li><strong>TP53 R273C：</strong> CRISPR敲入小鼠模型驗證成骨細胞惡性轉化</li>
        <li><strong>CDKN2A雙突變：</strong> 類器官模型測試聯合突變協同效應</li>
        <li><strong>B2M缺失：</strong> PD-1抑制劑在免疫缺陷模型療效評估</li>
    </ol>
    
    <h3>臨床轉化建議</h3>
    <ul>
        <li>開發TP53突變狀態作為術前化療反應預測生物標誌物</li>
        <li>探索ATRX缺失腫瘤的ALT（端粒延長替代機制）靶向療法</li>
        <li>MAP2K1突變患者納入MEK抑制劑臨床試驗</li>
    </ul>
</body>
</html>